Compare NetEase Inc (NTES) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs Sana Biotechnology Inc — how do they compare? NetEase Inc trades at $124.32 (market cap $76.09B), while Sana Biotechnology Inc trades at $2.84 (market cap $836.71M). The key difference: NetEase Inc is far larger — about 90.9× Sana Biotechnology Inc's market cap, and NetEase Inc pays a 2.45% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetEase Inc for 73 Days and Sana Biotechnology Inc for 23 Days on average.
| NTES | SANA | |
|---|---|---|
Market Cap | $76.09B | $836.71M |
Volume | 486,447 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $152.85 | $5.92 |
52-Week Low | $109.26 | $2.68 |
Typical Hold Time | 73 Days | 23 Days |
Enterprise Value | $51.81B | $749.96M |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTES trades at $124.20, up 2.98% today, with a neutral technical signal and mixed earnings history. The company reported Q2 2026 revenue growth of 8% year-over-year to $4.4 billion, though EPS missed expectations. Strong fundamentals include a 27.88% net income margin and robust cash flow from operations of $50.74 billion in 2025. Recent news highlights focus on gaming performance and AI investments.
Outlook remains positive with an 81.82% analyst buy rating and a $168.00 consensus price target, implying significant upside. Risks include earnings volatility and competitive pressures in the gaming sector. The stock presents a value opportunity given its reasonable P/E of 15.92 and strong balance sheet with $137.58 billion in cash.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
